Ocera Therapeutics (OCRX) Reports Q1 Loss Per Share of $0.28, Offers Guidance

Ocera Therapeutics (NASDAQ: OCRX) reported Q1 EPS of ($0.28), versus ($0.36) reported last year.

Financial Guidance

Ocera expects net use of cash for 2017 to be in the range of $24.0 million to $27.0 million, including $3.1 million in scheduled principal repayments on notes payable, and reiterates its previous guidance that it will have sufficient cash to fund operations into the second quarter of 2018 based on its current operating plan.

For earnings history and earnings-related data on Ocera Therapeutics (OCRX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• BNP Paribas Exane Downgrades Lanxess AG (LXS:GR) (LNXSF) to Underperform
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance